Our Research
The Chen Lab works at the intersection of multiple disciplines to study tissue fibrosis, with a focus on liver fibrosis. Activation of hepatic stellate cells (HSCs) is a central event in liver fibrogenesis, and our lab aims to identify novel mechanisms to inactivate HSCs as a therapeutic strategy. We have discovered exciting molecular targets and validated their roles using conditional knockout mice in multiple models of liver fibrosis, including models that recapitulate nonalcoholic steatohepatitis (NASH). Our lab has also demonstrated that HSCs play a critical role in collagen degradation.
A major focus of our lab is the development of new antifibrotic therapies, as no FDA-approved drugs currently exist that target fibrosis. In parallel, we have developed gene signature scores to identify patients with advanced fibrosis who may benefit from the therapies we are developing.
Our research combines mechanistic studies, translational models, and patient-oriented approaches to advance understanding and treatment of this disease. The Chen Lab is fueled by curiosity, collaboration, and a commitment to progressing the field of liver research.
Our Funding
Our work has been supported by multiple NIH grants (including 2 R01s and a U01 award), as well as funding from the UCSF InVent Fund, the Harrington Discovery Institute, and industry partners including Merck and Pliant.